Working… Menu
Trial record 29 of 174 for:    pertuzumab

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02060253
Recruitment Status : Completed
First Posted : February 12, 2014
Last Update Posted : June 14, 2018
National Cancer Institute (NCI)
Synta Pharmaceuticals Corp.
New York University Cancer Institute
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center